nejm semaglutide ckd flow trial kidney outcomes 2024 hazard ratio 0.76 clinical (funded by Novo Nordisk) New in the March 5,

If your symptoms appear right before your next dose, they are more likely to be an unrelated illness

3 , 7 In an analysis involving approximately 300000 individuals, Chou and coauthors reported that semaglutide use was not associated with an increased risk of NAION compared to nonGLP-1 RA users

A provider can evaluate your health history, metabolic profile, and weight-loss goals to determine whether this therapy aligns with your long-term plan for improved health and sustainability

Husain M, Birkenfeld AL, Donsmark M, et al, for the PIONEER 6 Investigators

Telehealth and patient satisfaction: a systematic review and narrative analysis